New hope to halt kidney damage in diabetics
NCT ID NCT07116928
Summary
This study is testing whether adding a medication called ganagliflozin to standard treatment can help slow the worsening of kidney disease in people who have both type 2 diabetes and chronic kidney disease. About 1,244 participants will take either ganagliflozin or a placebo (inactive pill) along with their usual care for 120 weeks. Researchers will compare how well the kidneys function over time and monitor for safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T2DM (TYPE 2 DIABETES MELLITUS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai sixth People's Hospital
Shanghai, Shanghai Municipality, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.